Form 4: CEO LeMaitre Reports LMAT Stock Transactions

Sentiment:

Insider Transaction Report


LeMaitre Vascular CEO George W. LeMaitre disclosed routine stock acquisitions and dispositions related to equity awards and tax obligations.

Summary

  • George W. LeMaitre, Chairman and CEO of LeMaitre Vascular Inc. (LMAT), reported several transactions involving the company's common stock and dividend equivalent rights.
  • On December 6, 2025, 11 shares of common stock were acquired upon the release of dividend equivalent rights.
  • Concurrently, 553 shares of common stock were disposed of on December 6, 2025, at a price of $84.53 per share, to satisfy tax withholding obligations incurred from the vesting of restricted stock units awarded on December 6, 2024.
  • Multiple dividend equivalent rights (DERs) were acquired on December 4, 2025, accruing on various restricted stock unit (RSU) and performance share unit (PSU) awards granted between December 11, 2021, and December 6, 2024.
  • Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock and vests proportionately with its underlying award.
  • The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating pre-scheduled activity.
  • Following these transactions, Mr. LeMaitre directly beneficially owns 1,665,032 shares of common stock and indirectly owns 21,300 shares through an irrevocable trust for his child(ren).

Sentiment

Score: 5

Explanation: The filing is neutral as it reports routine insider transactions related to executive compensation and tax obligations, which are standard disclosures and do not indicate any new positive or negative developments for the company.

Positives

  • The acquisition of shares and accrual of dividend equivalent rights reflect ongoing equity compensation for the CEO, aligning management's interests with shareholders.
  • The transactions were conducted under a Rule 10b5-1 plan, demonstrating a commitment to transparent and pre-scheduled trading practices.

Negatives

  • The disposition of 553 shares for tax withholding purposes represents a reduction in direct beneficial ownership, though it is a standard practice for equity compensation.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing is a routine disclosure of insider transactions and does not provide specific insights into broader industry trends or competitive landscape.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Insider Trading PolicyTransactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities, indicating pre-planned trading to avoid accusations of insider trading.N/AEnhances transparency and reduces potential for insider trading concerns by demonstrating pre-scheduled transactions.

Stakeholder Impact

  • Shareholders: The disclosure provides transparency regarding executive compensation and share ownership, which is a standard aspect of corporate governance.
  • Management: The transactions reflect the execution of pre-approved equity compensation plans for the CEO.

Key Dates

DateDescription
12/11/2021Grant date for a restricted stock unit award on which dividend equivalent rights accrued.
12/12/2022Grant date for restricted stock unit and performance share unit awards on which dividend equivalent rights accrued.
12/08/2023Grant date for restricted stock unit and performance share unit awards on which dividend equivalent rights accrued.
12/06/2024Grant date for a restricted stock unit award, which vested and led to tax withholding obligations.
12/04/2025Date of earliest transaction, involving the acquisition of several dividend equivalent rights.
12/06/2025Date of common stock acquisition (from DER release) and disposition (tax withholding), and release of 11 dividend equivalent rights.
12/08/2025Signature date of the Form 4 filing.

Recommendation

hold

This Form 4 details routine insider transactions related to equity compensation and tax obligations, which are standard for executives. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The transactions were conducted under a Rule 10b5-1 plan, indicating pre-scheduled activity rather than discretionary trading based on new material information.

Keywords

LEMAITRE VASCULAR, LMAT, Form 4, Insider Trading, Stock Transaction, CEO, George W. LeMaitre, Equity Compensation, Restricted Stock Units, Performance Share Units, Dividend Equivalent Rights, Tax Withholding, Rule 10b5-1

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.